Who are Sequential BCG and EMDA mitomycin C's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sequential-bcg-and-emda-mitomycin-c.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Sequential BCG and EMDA mitomycin C — Competitive Intelligence Brief

Sequential BCG and EMDA mitomycin C (Sequential BCG and EMDA mitomycin C) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination immunotherapy and chemotherapy. Area: Oncology.

phase 3 Combination immunotherapy and chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Sequential BCG and EMDA mitomycin C (Sequential BCG and EMDA mitomycin C) — Turku University Hospital. Sequential BCG immunotherapy followed by EMDA-enhanced mitomycin C chemotherapy provides combined immunological and chemotherapeutic effects for intravesical bladder cancer treatment.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sequential BCG and EMDA mitomycin C TARGET	Sequential BCG and EMDA mitomycin C	Turku University Hospital	phase 3	Combination immunotherapy and chemotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination immunotherapy and chemotherapy class)

Turku University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sequential BCG and EMDA mitomycin C — Competitive Intelligence Brief. https://druglandscape.com/ci/sequential-bcg-and-emda-mitomycin-c. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab